PE Corp. created Celera to exploit its high-productivity new sequencer, the Prism 3700, and build a broad set of proprietary genomic databases. The move instantly boosted sales of the new sequencer, paying for the expensive start-up in increased revenues to PE's PE Biosystems division and a dramatic increase in market value. Unlike its genomic database competitors, Celera won't charge subscribers royalties and milestones for successful use of the data. To encourage broad and continuing use of the system it hopes will become the industry standard, it plans to make money largely on subscription fees and enlarging its client base, not reach-through rights. But novel genetic data is just the hook for catching clients--Celera hopes to keep them subscribing with a program of continuous annotations and a set of bioinformatics tools that enable a level of in silico experimentation once requiring highly expensive in vitro and in vivo studies. But a raft of new and older competitors stand in the way of its bioinformatics ambitions.
by Roger Longman
A reporter takes away one overriding message when J. Craig Venter, PhD, leads him on a tour of PE Corp....
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
